Panbela Announces Issuance Of New Patent In China For Claims Of A Novel Process For The Production Of SBP-101
Portfolio Pulse from Benzinga Newsdesk
Panbela Therapeutics (NASDAQ:PBLA) has announced the issuance of a new patent in China for a novel process for the production of SBP-101, a lead investigational product. The patent, developed in collaboration with Syngene International Ltd., reduces the number of synthetic steps from seventeen to six, making the production more scalable, efficient, and cost-effective. The patent is valid until 2039 and is expected to improve the overall competitiveness of SBP-101 in the market.
September 26, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The new patent for the production of SBP-101 could potentially reduce production costs and improve the overall competitiveness of the product in the market. This could lead to increased opportunities for SBP-101's success and potentially boost Panbela's revenues.
The new patent allows for a more efficient production process of SBP-101, reducing costs and potentially increasing the product's competitiveness. This could lead to increased market access and revenues for Panbela.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100